GNE-9815

CAS No. 2729996-45-4

GNE-9815( 3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide )

Catalog No. M28781 CAS No. 2729996-45-4

GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 141 In Stock
5MG 141 In Stock
10MG 226 In Stock
25MG 377 In Stock
50MG 527 In Stock
100MG 714 In Stock
200MG Get Quote In Stock
500MG 1432 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GNE-9815
  • Note
    Research use only, not for human use.
  • Brief Description
    GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
  • Description
    GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
  • In Vitro
    GNE-9815 shows synergistic activity in KRAS mutant A549 and HCT116 cancer cells in combination with the MEK inhibitor Cobimetinib.
  • In Vivo
    GNE-9815 (15 mg/kg; p.o.; single) demonstrates synergistic MAPK pathway modulation when combines with the MEK inhibitor Cobimetinib in an HCT116 xenograft mouse model.GNE-9815 (5 mg/kg; p.o.; single) shows good oral bioavailability and (1 mg/kg; i.v.; single) exhibits low blood clearance, moderate volume of distribution, and short half-life. Animal Model:Female NCR nude mice (6 to 8-week-old; 24-26 g; HCT116 xenograft mice model).Dosage:15 mg/kgAdministration:Intravenous injection or oral administration; single.Result:Resulted in pathway inhibition as demonstrated by partial inhibition of pRSK between 2 and 24 h, but more robust, albeit transient, inhibition of the downstream MAPK target genes, DUSP6 and SPRY4.Led to deeper inhibition of the downstream MAPK target genes DUSP6 and SPRY4, when combined with the MEK inhibitor Cobimetinib, with maximal inhibition at 8 h and with a more modest rebound in levels at 24 h, post final dose.Animal Model:Female NCR nude mice (6 to 8-week-old; 24-26 g).Dosage:1 mg/kg (for i.v.); 5 mg/kg (for p.o.).Administration:Intravenous injection or oral administration; single.Result:Exhibited CLb, Vdss and t1/2 values of 17 mL/min?kg, 1.7 L/kg and 1.9 h, respectively.Showed good oral bioavailability with F% of 37%. (methylcellulose/Tween formulation).
  • Synonyms
    3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2729996-45-4
  • Formula Weight
    455.48
  • Molecular Formula
    C26H22FN5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (109.77 mM)
  • SMILES
    N#CC(C=1C=CC=C(C1)C(=O)NC=2C=C(C3=CN=C4C(C=NN(C4=O)C)=C3)C(=CC2F)C)(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Gong J, et al. Salvianolic acid Y: a new protector of PC12 cells against hydrogen peroxide-induced injury from Salvia officinalis. Molecules. 2015 Jan 6;20(1):683-92.
molnova catalog
related products
  • SB-590885

    A potent and selective B-Raf inhibitor with Kd of 0.3 nM.

  • CCT241161

    CCT241161 is a potent pan-RAF inhibitor with IC50 of 30, 15 and 6 nM for BRAF, V600E-BRAF and C-RAF.

  • Compound 23

    Compound 23 selectively induces degradation of BRAF-V600E but not wildtype BRAF.